Drug Landscape ›
Baby aspirin ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11,836
Most-reported reactions
Drug Ineffective — 1,644 reports (13.89%) Fatigue — 1,456 reports (12.3%) Nausea — 1,229 reports (10.38%) Dyspnoea — 1,173 reports (9.91%) Dizziness — 1,166 reports (9.85%) Diarrhoea — 1,154 reports (9.75%) Headache — 1,085 reports (9.17%) Pain — 1,007 reports (8.51%) Off Label Use — 1,002 reports (8.47%) Asthenia — 920 reports (7.77%)
Source database →
Baby aspirin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Baby aspirin approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Baby aspirin in United States?
Emory University is the originator. The local marketing authorisation holder may differ — check the official source linked above.